Tenaya Therapeutics, Inc. SEC Filings

Tenaya Therapeutics Chief Medical Officer Tingley Whittemore reported a small share sale primarily tied to taxes. On the reported date, Whittemore sold 3,121 shares of common stock at $0.7936 per share to cover tax withholding obligations related to vesting restricted stock units awarded on January 24, 2025.

After this transaction, Whittemore held 215,497 shares of Tenaya Therapeutics common stock directly, which includes 112,919 shares that will be issued upon future vesting of restricted stock units. The filing reflects a routine, tax-driven disposition rather than a large change in overall ownership.

Tenaya Therapeutics, Inc. SVP of Finance Tomohiro Higa reported an open-market sale of 1,485 shares of common stock on May 18, 2026 at an average price of $0.7932 per share. According to the disclosure, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on August 15, 2024.

After this transaction, Higa directly holds 118,267 shares of Tenaya common stock. This figure includes 67,938 shares that will be issued to him upon future vesting of restricted stock units, indicating that the sale represents a small portion of his overall equity exposure.

Tenaya Therapeutics reported a smaller quarterly loss while adding its first collaboration revenue and a major new research partnership. For the three months ended March 31, 2026, net loss was $19.3 million, improving from $26.9 million a year earlier as research and development and general and administrative expenses fell about 30% and 16%, respectively. The company ended the quarter with $80.9 million in cash and cash equivalents and believes this will fund operations for at least twelve months. Tenaya recorded $0.2 million of collaboration revenue and set up $10.4 million of contract liabilities tied mainly to a new multi-target cardiovascular discovery collaboration with Alnylam, which includes a fixed $10.0 million upfront platform access fee and potential milestones of up to $1.1 billion. Management continues to focus spending on its three lead programs TN-201, TN-401 and TN-301 while progressing early-stage pipeline and maintaining one operating segment.

Tenaya Therapeutics reported first quarter 2026 results and a broad pipeline update. Collaboration revenue was $225,000, total operating expenses were $20.3 million, and net loss narrowed to $19.3 million, or $0.09 per share, compared with a $26.9 million loss a year earlier.

Cash and cash equivalents were $80.9 million as of March 31, 2026, and together with a $10.0 million upfront payment from a new Alnylam collaboration are expected to fund operations into the second half of 2027. The company highlighted upcoming 2026 data readouts for gene therapies TN-201 and TN-401, preclinical progress for TN-301, and design-stage work on gene editing candidate TN-501.

Tenaya Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on May 27, 2026. The agenda includes electing three Class II directors to serve until 2029, ratifying Deloitte & Touche LLP as auditor for the year ending December 31, 2026, and approving changes to the 2021 Equity Incentive Plan.

The amended and restated plan would add 6,509,966 shares of common stock, described as approximately 3% of outstanding shares, to the shares reserved for issuance and remove the 4 million share annual limit from the plan’s 4% “evergreen” increase. The board currently has eight members, seven deemed independent, and recommends voting “FOR” all three proposals.

Tenaya Therapeutics files its Annual Report describing a focused strategy to develop disease‑modifying therapies for heart disease, centered on genetic drivers of cardiomyopathies. The company is advancing three clinical‑stage programs: gene therapies TN‑201 for MYBPC3‑associated hypertrophic cardiomyopathy and TN‑401 for PKP2‑associated arrhythmogenic right ventricular cardiomyopathy, and small‑molecule HDAC6 inhibitor TN‑301 for HFpEF and other cardiac and muscular disorders.

Interim Phase 1b/2 data suggest TN‑201 and TN‑401 can increase target protein expression and improve biomarkers and arrhythmia measures, with generally manageable safety. Tenaya also highlights broad platform capabilities in iPSC disease models, capsid engineering, cardiac‑specific promoters, and in‑house AAV manufacturing. A new multi‑target collaboration with Alnylam includes up to $10.0 million in upfront payments and up to $1.13 billion in potential milestones, reinforcing its role as a specialist partner in cardiovascular genetics. As of June 2025, non‑affiliate equity was valued at approximately $63.1 million, with 216,998,876 common shares outstanding as of March 2026.

Tenaya Therapeutics reported 2025 results showing tighter spending, new partnerships and a stronger balance sheet. Net loss narrowed to $90.6 million, or $0.59 per share, from $111.1 million, or $1.31 per share, in 2024 as operating expenses declined.

Cash, cash equivalents and marketable securities rose to $100.5 million as of December 31, 2025, helped by a December underwritten offering of 50,000,000 units at $1.20 per unit, generating net proceeds of $55.8 million. Together with an expected upfront payment from a new Alnylam collaboration, the company expects to fund operations into the second half of 2027.

Tenaya highlighted encouraging early clinical data from gene therapies TN‑201 for MYBPC3‑associated hypertrophic cardiomyopathy and TN‑401 for PKP2‑associated arrhythmogenic right ventricular cardiomyopathy, as well as preclinical results for TN‑301 in Duchenne muscular dystrophy models. Multiple data readouts and steps toward pivotal trial planning are anticipated during 2026.

Tenaya Therapeutics entered a major collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for potential cardiovascular therapies. The parties will nominate 15 targets and run a 24‑month research program with in vitro and in vivo validation under an agreed plan and budget.

Alnylam will reimburse Tenaya’s full-time employee and out-of-pocket research costs and will take over all later development, manufacturing, regulatory and commercialization work for products from collaboration targets. Tenaya grants Alnylam an exclusive worldwide license to use collaboration targets and related know‑how.

Tenaya will receive an upfront payment of up to $10.0 million, subject to $500,000 reductions for up to eight company‑nominated targets that do not meet agreed standards, and is eligible for up to $1.13 billion in development, regulatory and sales‑based milestones tied to company‑nominated targets. The agreement includes target‑level termination mechanics, exclusivity limits on Tenaya’s own work on certain targets, standard IP protections, indemnities, and allows Alnylam to terminate the collaboration unilaterally with notice.